GNE-0723 – (1883518-31-7)

GNE-0723 is a brain-permeable positive allosteric modulator of NMDAR, specifically targeting GluN2A-containing receptors.

Research indicates that GNE-0723 enhances synaptic NMDA receptor currents, reduces abnormal low-frequency brain oscillations, and improves cognitive functions in mouse models of Dravet syndrome and Alzheimer’s disease.

The compound has shown potential in reducing epileptiform activity and improving memory and learning, making it a promising candidate for further research in neurological disorders.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

GNE-0723 is a brain-permeable positive allosteric modulator of NMDAR, specifically targeting GluN2A-containing receptors.

Research indicates that GNE-0723 enhances synaptic NMDA receptor currents, reduces abnormal low-frequency brain oscillations, and improves cognitive functions in mouse models of Dravet syndrome and Alzheimer’s disease.

The compound has shown potential in reducing epileptiform activity and improving memory and learning, making it a promising candidate for further research in neurological disorders.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://www.medchemexpress.com/GNE_0723.html
https://www.medkoo.com/products/8253
https://pubmed.ncbi.nlm.nih.gov/31940483/
https://www.alzforum.org/news/research-news/could-new-glutamate-receptor-activators-treat-alzheimers

Other Names	GNE 0723, CHEMBL3799213, (1R, 2R)-2-[7-[[5-chloro-3-(trifluoromethyl)pyrazol-1-yl]methyl]-5-oxo-2-(trifluoromethyl)-[1, 3]thiazolo[3, 2-a]pyrimidin-3-yl]cyclopropane-1-carbonitrile
IUPAC Name	(1R, 2R)-2-[7-[[5-chloro-3-(trifluoromethyl)pyrazol-1-yl]methyl]-5-oxo-2-(trifluoromethyl)-[1, 3]thiazolo[3, 2-a]pyrimidin-3-yl]cyclopropane-1-carbonitrile
CAS	1883518-31-7
Molecular Weight	467.8
Molecular Formula	C16H8ClF6N5OS
SMILES	C1[C@H]([C@@H]1C2=C(SC3=NC(=CC(=O)N23)CN4C(=CC(=N4)C(F)(F)F)Cl)C(F)(F)F)C#N

Products

Consulting & Services

Check Out Our Research And Updates

GNE-0723 – (1883518-31-7)

GNE-0723 is a brain-permeable positive allosteric modulator of NMDAR, specifically targeting GluN2A-containing receptors.

Research indicates that GNE-0723 enhances synaptic NMDA receptor currents, reduces abnormal low-frequency brain oscillations, and improves cognitive functions in mouse models of Dravet syndrome and Alzheimer’s disease.

The compound has shown potential in reducing epileptiform activity and improving memory and learning, making it a promising candidate for further research in neurological disorders.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://www.medchemexpress.com/GNE_0723.html
https://www.medkoo.com/products/8253
https://pubmed.ncbi.nlm.nih.gov/31940483/
https://www.alzforum.org/news/research-news/could-new-glutamate-receptor-activators-treat-alzheimers

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

GNE-0723 – (1883518-31-7)

GNE-0723 is a brain-permeable positive allosteric modulator of NMDAR, specifically targeting GluN2A-containing receptors.

Research indicates that GNE-0723 enhances synaptic NMDA receptor currents, reduces abnormal low-frequency brain oscillations, and improves cognitive functions in mouse models of Dravet syndrome and Alzheimer’s disease.

The compound has shown potential in reducing epileptiform activity and improving memory and learning, making it a promising candidate for further research in neurological disorders.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://www.medchemexpress.com/GNE_0723.html https://www.medkoo.com/products/8253 https://pubmed.ncbi.nlm.nih.gov/31940483/ https://www.alzforum.org/news/research-news/could-new-glutamate-receptor-activators-treat-alzheimers

Related products

Quick Contact

https://www.medchemexpress.com/GNE_0723.html
https://www.medkoo.com/products/8253
https://pubmed.ncbi.nlm.nih.gov/31940483/
https://www.alzforum.org/news/research-news/could-new-glutamate-receptor-activators-treat-alzheimers